Machina Capital’s Integra LifeSciences IART Stock Holding History

Machina Capital’s Portfolio IART Stock Details IART Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-6,965	Closed	-$406K	–	135
2019 Q4	$406K	Buy	+6,965	New	+$415K	0.16%	220
2019 Q2	–	Sell	-650	Closed	-$36K	–	552
2019 Q1	$36K	Buy	+650	New	+$33.1K	0.01%	375

Other funds holding IART

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Cooke & Bieler Philadelphia, Pennsylvania $8.84B AUM 6.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Machina Capital's IART Position: Q1 2020 in Review

Machina Capital sold out of Integra LifeSciences (IART) in Q1 2020, closing a stake of 6,965 shares — an estimated $406K sold.

Machina Capital first reported a position in IART in Q1 2019 and held it in 2 quarters. The position peaked at $406K in Q4 2019. 258 funds tracked by Wall St. Rank hold IART as of Q1 2020.

Machina Capital reported no remaining Integra LifeSciences position as of Q1 2020 after selling out during the quarter.
Machina Capital sold 6,965 Integra LifeSciences shares in Q1 2020, an estimated $406K.
Machina Capital first reported a position in Integra LifeSciences in Q1 2019 and held it in 2 quarters.
Machina Capital's Integra LifeSciences position peaked at $406K in Q4 2019.
258 funds tracked by Wall St. Rank held Integra LifeSciences as of Q1 2020.

Based on Machina Capital's 13F filing for Q1 2020.